CERVOMED INC. - COMMON

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

12 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

30 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

29 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference

17 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

11 июл 2024 08:51:12 Источник Nasdaq GlobeNewswire

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes

24 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

11 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Appoint William Elder as Chief Financial Officer

20 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

01 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

28 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

28 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

05 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Participate in the BIO CEO and Investor Conference

21 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

12 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

07 фев 2024 08:30:00 Источник Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference 67

05 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference 66

05 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire